FDA Drug Label
VYLEESI (bremelanotide injection) for subcutaneous use - Prescribing Information
AMAG, 2019
Sexual HealthFDA ApprovedS
PT-141
Bremelanotide / Vyleesi
PT-141 (bremelanotide, brand: Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, PT-141 acts centrally on melanocortin receptors in the CNS to increase sexual desire and arousal rather than acting peripherally on blood flow. Administered as a subcutaneous autoinjector 45 minutes before anticipated sexual activity. Banned from 503A compounding pharmacies.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 7
- Research grade
- S
- Experience
- 15
- Activity
- 63
Overall check-ins
Trackers & reports
Overview
About PT-141
PT-141 (bremelanotide, brand: Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, PT-141 acts centrally on melanocortin receptors in the CNS to increase sexual desire and arousal rather than acting peripherally on blood flow. Administered as a subcutaneous autoinjector 45 minutes before anticipated sexual activity. Banned from 503A compounding pharmacies.
- Category
- Sexual Health
- Regulatory status
- FDA Approved
- Also known as
- Bremelanotide / Vyleesi
- Self-reports
- 29
Community
What 29 users report
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 4% · Mixed 3% · Unfavorable overall 93%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Libido
115
Mood
2
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
38
Headache
37
Injection site irritation
35
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
1
0.2–0.4 mg
2
0.4–0.6 mg
9
0.6–1 mg
3
1–2 mg
9
2–3 mg
90
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 100 days · Based on 23 repeat reporters
Research
Cited research (5)
Source
PubMed
Bremelanotide: New Drug for Treating Hypoactive Sexual Desire Disorder
Kingsberg et al., 2019
ClinicalTrials.gov
Bremelanotide (PT-141) studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
Pettigrew et al., 2021
PubMed
Pharmacologic therapeutic options for sexual dysfunction
Burton et al., 2022
Tools
Explore more
Explore
More ways to learn about PT-141 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about PT-141?
This page summarizes 29 anonymized self-reports from PeptIQ users who track PT-141, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for PT-141?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for PT-141?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is PT-141 safe to use?
This wiki does not assess safety or recommend use. PT-141 is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of PT-141?
This wiki summarizes observational community reports and linked citations for PT-141. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for PT-141 for study-level context — not medical advice.
What is the legal status of PT-141?
PT-141 is listed in PeptIQ as FDA Approved. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of PT-141?
Safety data quality for PT-141 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on PT-141?
This page links 5 indexed sources for PT-141. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.